Comparison of Serum Adiponectin and Tumor Necrosis Factor-Alpha Levels between Patients with and without Obstructive Sleep Apnea Syndrome

Kanbay, Asiye; Köktürk, Oğuz; Çiftçi, Tansu Ulukavak; Tavıl, Yusuf; Bukan, Neslihan

doi:10.1159/000134010

Cited by 44 publications

(34 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In obese subjects, the adiponectin level is decreased and inversely correlated with both body weight and fat mass [6,16,17]. In contrast, it has been reported that plasma adiponectin levels are elevated in underweight subjects such as patients with anorexia nervosa [18] and cachexia [19].…”

Section: Discussionmentioning

confidence: 99%

Elevated Serum Adiponectin Level in Patients with <i>Mycobacterium avium-intracellulare</i> Complex Pulmonary Disease

et al. 2009

View full text Add to dashboard Cite

Background: Patients with Mycobacterium avium-intracellulare complex (MAC) pulmonary disease often suffer from weight loss. Adipokines are factors secreted by adipocytes, including leptin and adiponectin, as well as some inflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6). Body mass index (BMI) is known to be inversely correlated with adiponectin and positively with leptin, TNF-α, and IL-6. Objective: We aimed to evaluate the levels of serum adipokines, including adiponectin, leptin, TNF-α, and IL-6 in patients with MAC pulmonary disease. Methods: Forty consecutive patients with MAC pulmonary disease (8 males; median age 62 years; median BMI 18.1) were examined. Serum levels of adiponectin, leptin, TNF-α, and IL-6 were measured with ELISA. Age-, sex- and BMI-matched healthy subjects served as controls. Results: Serum adiponectin was significantly elevated in patients with MAC pulmonary disease compared with the controls (p < 0.01). In both the patients and controls, serum adiponectin levels were inversely correlated with BMI (p < 0.05). No significant correlation was observed between serum adiponectin levels and C-reactive protein or lung function. Serum leptin levels, which were positively correlated with BMI, did not differ between patients and controls. Serum levels of TNF-α and IL-6 were significantly greater in patients with MAC pulmonary disease than in controls. The levels of TNF-α and IL-6 were not correlated with BMI and other adipokines examined. Conclusion: The results of the present study indicate that, in patients with MAC pulmonary disease, adiponectin is inappropriately secreted and may play a role in the pathophysiology of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Elevated Serum Adiponectin Level in Patients with <i>Mycobacterium avium-intracellulare</i> Complex Pulmonary Disease

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Adiponectin, a metabolically protective adipokine, was found to be decreased in OSA patients compared to controls in proportion to the severity of nocturnal hypoxaemia [166][167][168], suggesting a possible pathophysiological role of oxidative stress in decreased adiponectin levels in OSA. Other studies, however, reported a closer relationship of low adiponectin levels with obesity than with OSA [165,169].…”

Section: Ir and Mets In Osamentioning

confidence: 95%

Adipose tissue in obesity and obstructive sleep apnoea

Bonsignore¹,

McNicholas²,

Montserrat³

et al. 2011

European Respiratory Journal

112

View full text Add to dashboard Cite

A European Respiratory Society research seminar on ''Metabolic alterations in obstructive sleep apnoea (OSA)'' was jointly organised in October 2009 together with two EU COST actions (Cardiovascular risk in the obstructive sleep apnoea syndrome, action B26, and Adipose tissue and the metabolic syndrome, action BM0602) in order to discuss the interactions between obesity and OSA.Such interactions can be particularly significant in the pathogenesis of metabolic abnormalities and in increased cardiovascular risk in OSA patients. However, studying the respective role of OSA and obesity is difficult in patients, making it necessary to refer to animal models or in vitro systems. Since most OSA patients are obese, their management requires a multidisciplinary approach.This review summarises some aspects of the pathophysiology and treatment of obesity, and the possible effects of sleep loss on metabolism. OSA-associated metabolic dysfunction (insulin resistance, liver dysfunction and atherogenic dyslipidaemia) is discussed from the perspective of both obesity and OSA in adults and children.Finally, the effects of treatment for obesity or OSA, or both, on cardio-metabolic variables are summarised. Further interdisciplinary research is needed in order to develop new comprehensive treatment approaches aimed at reducing sleep disordered breathing, obesity and cardiovascular risk.

show abstract

“…Several other studies have demonstrated lower levels of APN in OSAS patients and subsequent improvement following CPAP therapy [104][105][106][107][108][109][110]. However, not all studies have shown an association between OSAS and APN [111][112][113][114][115].…”

Section: Clinical Studiesmentioning

confidence: 99%

Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation

Garvey

Taylor²,

McNicholas

2009

European Respiratory Journal

312

225

View full text Add to dashboard Cite

There is increasing evidence that intermittent hypoxia plays a role in the development of cardiovascular risk in obstructive sleep apnoea syndrome (OSAS) through the activation of inflammatory pathways. The development of translational models of intermittent hypoxia has allowed investigation of its role in the activation of inflammatory mechanisms and promotion of cardiovascular disease in OSAS. There are noticeable differences in the response to intermittent hypoxia between body tissues but the hypoxia-sensitive transcription factors hypoxia-inducible factor-1 and nuclear factor-kB appear to play a key role in mediating the inflammatory and cardiovascular consequences of OSAS. Expanding our understanding of these pathways, the cross-talk between them and the activation of inflammatory mechanisms by intermittent hypoxia in OSAS will provide new avenues of therapeutic opportunity for the disease.

show abstract

Comparison of Serum Adiponectin and Tumor Necrosis Factor-Alpha Levels between Patients with and without Obstructive Sleep Apnea Syndrome

Cited by 44 publications

References 44 publications

Elevated Serum Adiponectin Level in Patients with <i>Mycobacterium avium-intracellulare</i> Complex Pulmonary Disease

Elevated Serum Adiponectin Level in Patients with <i>Mycobacterium avium-intracellulare</i> Complex Pulmonary Disease

Adipose tissue in obesity and obstructive sleep apnoea

Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation

Contact Info

Product

Resources

About